Reactivity testing was carried out by indirect fluorescent-antibody (FA) at 10 µg/ml.
MOUSE ANTI-RHINOVIRUS VP3 ANTIBODY (4965)
Mouse anti Rhinovirus VP3 antibody (4965) is specific for the VP3 of numerous Rhinovirus types. The antibody is suitable for enzyme immunoassay (EIA) applications.
PRODUCT DETAILS – MOUSE ANTI-RHINOVIRUS VP3 ANTIBODY (4965)
- Mouse anti Rhinovirus VP3 (4965) monoclonal antibody.
- Not reactive with other Enteroviruses (5), Influenza A, Influenza B, RSV, Adenovirus, Para 1, Para 2, Para 3, Chlamydia pneumoniae, Mycoplasma pneumoniae & Hepatitis A virus.
- Suitable for use in ELISA and IFA applications.
- Purified by Protein G Sepharose chromatography.
- Presented in phosphate buffered saline, pH 7.1, 0.1% sodium azide.
BACKGROUND
Human rhinoviruses (HRVs) were first discovered in the 1950s and belong to the genus Enterovirus in the family Picornaviridae. They are the most common viral infectious agent in humans and the predominant cause of the common cold. Rhinovirus infection proliferates in temperatures of 33–35 °C (91–95 °F), the temperatures found in the nose. There are three species of rhinovirus (A, B, and C) which include around 160 recognized types of human rhinoviruses that differ according to their surface proteins (serotypes). They are positive-sense, single-stranded-RNA (ssRNA) viruses of approximately 7,200 bp. The viral genome consists of a single gene whose translated protein is cleaved by virally encoded proteases to produce 11 proteins. Four proteins, VP1, VP2, VP3, and VP4, make up the viral capsid that encases the RNA genome, while the remaining non-structural proteins are involved in viral genome replication and assembly. The VP1, VP2, and VP3 proteins account for the virus’ antigenic diversity, while VP4 anchors the RNA core to the capsid. The viral particles themselves are not enveloped and there are 60 copies each of the four capsid proteins, giving the virion an icosahedral structure.
There are currently no approved vaccine or antiviral agents for the prevention or treatment of HRV infection. Vaccine development has proved difficult due to the high number of HRV serotypes which have high-level sequence variability in the antigenic sites (Jacobs et al., 2013).
The Native Antigen Company has created a range of enterovirus reagents to help researchers develop better serological testing methods for the diagnosis of enteroviral diseases.
REFERENCES
Powered by Bioz